A Canterbury study found inconsistent riluzole prescribing and monitoring in ALS
Original source
Prescribing and monitoring of riluzole in amyotrophic lateral sclerosis: a retrospective cohort study from Health New Zealand - Te Whatu Ora Waitaha Canterbury. (opens in a new tab)Compass summarised this from the study's abstract.
Study details
- Studied in
- Human
A retrospective study of 115 people with amyotrophic lateral sclerosis (ALS) diagnosed in Canterbury between 2020 and 2024 found that 69 people were prescribed riluzole. Fewer than 45% had baseline blood tests, and fewer than 60% completed recommended monitoring tests at all follow-up points. Eight people reported side effects, and three stopped treatment after liver-enzyme abnormalities were identified.
Why this matters
The findings may help Canterbury services review how riluzole is prescribed and monitored. They do not show that riluzole is unsafe or ineffective, and the study does not establish whether inconsistent monitoring affected patient outcomes.
Limitations and context
This was a retrospective review of electronic health and prescribing records from one Canterbury hospital database, involving 115 people. It assessed adherence to recommendations rather than treatment effectiveness, and excluded people with incomplete data. The findings may not apply to other regions or healthcare systems.